Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01466179 · ClinicalTrials.gov registry record · Phase 2
Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)
A Phase 2 study, sponsored by Amgen Research (Munich).
- Completed
- Registry status
- Phase 2
- Development phase
- 225
- Enrollment target
NCT01466179 is a Phase 2 study that has completed, run by Amgen Research (Munich). The registered enrollment target is 225 participants.
The verdict
NCT01466179, a Phase 2 study, has completed, sponsored by Amgen Research (Munich).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 225 participants
- Enrollment target
Study Summary
The purpose of this study is to confirm whether the bispecific T cell engager antibody blinatumomab (MT103) is effective and safe in the treatment of patients with relapsed or refractory Acute Lymphoblastic Leukemia (ALL).
Interventions
- BIOLOGICAL Blinatumomab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 225 participants |
| Start Date | 2011-12 |
| Est. Completion | 2017-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01466179
The ClinicalTrials.gov registry entry for NCT01466179 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 225 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen Research (Munich), which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Blinatumomab is the first listed.
NCT01466179 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01466179 about?
NCT01466179 is a clinical study titled "Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)". The purpose of this study is to confirm whether the bispecific T cell engager antibody blinatumomab (MT103) is effective and safe in the treatment of patients with relapsed or refractory Acute Lymphoblastic Leukemia (ALL).
What is the current status of trial NCT01466179?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 225 participants. The study started on 2011-12. Estimated completion is 2017-01.
What interventions are being tested in trial NCT01466179?
The interventions under investigation include: Blinatumomab (BIOLOGICAL).
Who is sponsoring clinical trial NCT01466179?
This trial is sponsored by Amgen Research (Munich), which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.